Trials / Completed
CompletedNCT01657019
Open Label Extension in Adults With Binge Eating Disorder (BED)
A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 604 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of SPD489 administered as a daily morning dose (50 or 70mg) in the treatment of moderate to severe binge eating disorder (BED) in adults
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lisdexamfetamine dimesylate | 50 or 70 mg administered orally, once a day for 52 weeks |
Timeline
- Start date
- 2012-08-21
- Primary completion
- 2014-10-21
- Completion
- 2014-10-21
- First posted
- 2012-08-03
- Last updated
- 2021-06-09
- Results posted
- 2015-12-15
Locations
89 sites across 3 countries: United States, Germany, Spain
Source: ClinicalTrials.gov record NCT01657019. Inclusion in this directory is not an endorsement.